Number of Participants Showing a 50% Reduction in Serum Prostate Specific Antigen(PSA) During Treatment up to one year [clinicaltrials_resource:ce6a50bf88d2e15c3d0a01450cdb0ba4]
Clinical trial summary from the National Cancer Institute's PDQ® database
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
Number of Participants Showing a 50% Reduction in Serum Prostate Specific Antigen(PSA) During Treatment up to one year [clinicaltrials_resource:ce6a50bf88d2e15c3d0a01450cdb0ba4]
Clinical trial summary from the National Cancer Institute's PDQ® database
Bio2RDF identifier
ce6a50bf88d2e15c3d0a01450cdb0ba4
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:ce6a50bf88d2e15c3d0a01450cdb0ba4
measure [clinicaltrials_vocabulary:measure]
Number of Participants Showing ...... Antigen(PSA) During Treatment
time frame [clinicaltrials_vocabulary:time-frame]
up to one year
description
Clinical trial summary from the National Cancer Institute's PDQ® database
identifier
clinicaltrials_resource:ce6a50bf88d2e15c3d0a01450cdb0ba4
title
Number of Participants Showing ...... uring Treatment up to one year
@en
type
label
Number of Participants Showing ...... a50bf88d2e15c3d0a01450cdb0ba4]
@en